Thank you to our speakers, sponsors, and delegates who joined us in Philadelphia! If you are interested in the 2026 event, please get in touch at: info@hansonwade.com
Power Targeted Therapeutic & Clinical Breakthroughs Across Different Autoimmune Cell Therapies with Proven Safety, Sustained Efficacy, & Greater Patient Access to Redefine Chronic Care of Autoimmune Diseases
Ever since cell therapies demonstrated potential in lupus and beyond, focus has shifted from oncology to advancing the first approved autoimmune cell therapy to market.
The 3rd Cell Therapy for Autoimmune Disease Summit returned at a transformative moment for this field, as autoimmune therapies stood poised to lead the next frontier of cell therapy innovation. In 2025, peers joined in spotlighting breakthroughs across CAR-T, Treg, NK and in vivo cell therapies, to gain end-to-end insights and navigate the dynamic, high-velocity road to market.
Attendees uncovered first-hand experiences from industry titans including Cabaletta Bio, Umoja Biopharma, Cartesian Therapeutics, Century Therapeutics, Artiva Biotherapeutics and Novartis, accelerated their therapeutic progression, and remained ahead of their peers.
From target selection and IND preparation to clinical trial design, patient recruitment, and long-term data, the 2025 event empowered teams to translate clinical promise into real breakthroughs.
This summit was extremely informative and collaborative. There were plenty of opportunities to network and engage in diverse sessions, spanning basic and clinical science
Vice President, Cullinan Therapeutics, Past Attendee
The 2025 World-Class Speaker Faculty Included:
Warren Li
Senior Vice President, Head of Preclinical Research & Project Leadership
Overland Therapeutics
Who Did You Meet in 2025?
2025 Partners:
The meeting last year was outstanding as a way to keep abreast of this fast-moving space in a very collegial environment
Chief Executive Officer, iCellGene Therapeutics, Past Attendee
It was very nice to have active leaders in the CAR-T space share their learnings and challenges in an open forum with an emphasis on collaboration
Associate Director, TG Therapeutics, Past Attendee
